Search Filters

Search Results

Found 2 results

510(k) Data Aggregation

    K Number
    K122764
    Device Name
    RAPID STRAND RX
    Manufacturer
    Date Cleared
    2012-12-28

    (109 days)

    Product Code
    Regulation Number
    892.5730
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    RAPID Strand ™ Rx is indicated for permanent interstitial implantation of selected localized tumors which are of low to moderate radiosensitivity. They may be used either as primary treatment (such as for prostate cancer or unresectable turnors) or for treatment of residual disease after excision of the primary tumor.

    RAPID Strand TM Rx may be indicated for use concurrent with or at the completion of other treatment modalities, such as external bear or adiation therapy or chemotherapy.

    Device Description

    This Special 510(k) is for the addition of a loading services provider, addition of bone wax needle plugging material and removal of a seed design.

    AI/ML Overview

    The provided text describes a 510(k) submission for a medical device called RAPID Strand Rx. The submission is not for a new device requiring extensive performance studies but for modifications to an already cleared device. Specifically, this Special 510(k) is for:

    1. Addition of a loading services provider.
    2. Addition of bone wax needle plugging material.
    3. Removal of a seed design.

    The central claim is that the modified device is "substantially equivalent" to its predicate device (RAPID Strand Rx, K063177). Therefore, the study described focuses on demonstrating this substantial equivalence rather than proving new performance criteria in a clinical setting.

    Given this context, many of the requested categories for acceptance criteria and study details (like sample size for test set, number of experts, MRMC studies, standalone performance with AI, training set details) are not applicable to this type of submission. This 510(k) is not about evaluating a diagnostic algorithm or a device with measurable performance metrics in the way those questions imply.

    Here's an attempt to answer based on the available information:

    1. A table of acceptance criteria and the reported device performance

      Acceptance CriteriaReported Device Performance
      Substantial Equivalence to Predicate Device (K063177)Medi-Physics Inc. concluded that the device is substantially equivalent to the predicate device.
      Safety and EffectivenessMedi-Physics Inc. concluded that the device is safe and effective for its intended use.
      Technological Characteristics of Bone Wax FormulationSubject to design controls and risk management. All identified hazards have been sufficiently mitigated. All results are acceptable.
    2. Sample size used for the test set and the data provenance (e.g., country of origin of the data, retrospective or prospective)
      Not applicable (N/A). This 510(k) is for modifications to an existing device and relies on engineering assessments and substantial equivalence, not a clinical test set with patient data.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g., radiologist with 10 years of experience)
      Not applicable (N/A). Ground truth as typically defined for a diagnostic study is not established here. The assessment is based on design controls and risk management for the modifications.

    4. Adjudication method (e.g., 2+1, 3+1, none) for the test set
      Not applicable (N/A). No test set requiring expert adjudication is described.

    5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
      Not applicable (N/A). This device is a radionuclide brachytherapy source, not an AI-powered diagnostic tool, and no MRMC study is mentioned or relevant to this submission type.

    6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
      Not applicable (N/A). This is not a standalone algorithm.

    7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
      The "ground truth" here is the established safety and performance of the predicate device, against which the modified device's technological characteristics (specifically the bone wax formulation) were assessed through design controls and risk management. It's not a clinical ground truth but rather an engineering and regulatory "ground truth" of substantial equivalence.

    8. The sample size for the training set
      Not applicable (N/A). There is no training set for an algorithm mentioned.

    9. How the ground truth for the training set was established
      Not applicable (N/A). There is no training set for an algorithm mentioned.

    Ask a Question

    Ask a specific question about this device

    K Number
    K081066
    Date Cleared
    2008-05-05

    (20 days)

    Product Code
    Regulation Number
    892.5730
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Brachytherapy Source Device, with apparent activities between 0.19mCi and 1.01mCi, is indicated for permanent interstitial implantation of selected localized tumors which are of low to moderate radiosensitivity. They may be used either as primary treatment (such as for prostate cancer or unresectable tumors) or for treatment of residual disease after excision of the primary tumor. Seeds in this apparent activity range may be used to treat superficial, intra-abdominal, and intra-thoracic tumors. Tumors of the head, neck, lung, pancreas and prostate (early stages) are commonly treated.

    The Brachytherapy Source Device, with total apparent activities greater than 1.01mCi, is indicated for interstitial treatment of tumors which have the following characteristics; unresectable, localized, and moderate radiosensitivity. These seeds may be used for selected radiation applications as temporary implants.

    The Brachytherapy Source Device is indicated to treat residual tumors concurrent with or at the completion of other treatment modalities, such as external beam radiation therapy or chemotherapy. In addition, recurrent tumors may be implanted with seeds.

    Device Description

    The Brachytherapy Source Device, Model 9011, is a welded titanium capsule containing Iodine-125 adsorbed onto a silver rod.

    AI/ML Overview

    Here's an analysis of the provided text regarding the Brachytherapy Source Device, Model 9011.

    It's important to note that this document is a 510(k) summary for a medical device, specifically a brachytherapy source. Brachytherapy sources are physical objects that emit radiation for cancer treatment, not a diagnostic AI/ML algorithm. Therefore, many of the requested categories related to AI/ML software performance (like effect size of AI assistance, MRMC studies, ground truth establishment for training, etc.) are not applicable to this type of device. The acceptance criteria and "studies" are focused on the physical characteristics and safety of the radiation source itself, not its diagnostic accuracy or AI performance.


    Acceptance Criteria and Device Performance (Brachytherapy Source Device, Model 9011)

    1. Table of Acceptance Criteria and Reported Device Performance

    CharacteristicAcceptance Criteria (Predicate OncoSeed, Model 6711)Reported Device Performance (Brachytherapy Source Device, Model 9011)
    Seeds
    Regulatory StatusK914281 (Cleared)Subject Application
    Capsule MaterialTitanium, type A-40Titanium, type A-40
    Capsule Length4.20 - 4.90mm (0.165 - 0.193in)4.20 - 4.90mm (0.165 - 0.193in)
    Capsule Wall Thickness0.051 - 0.0635mm (0.002 - 0.0025in)0.051 - 0.0635mm (0.002 - 0.0025in)
    Capsule Diameter0.77 - 0.96mm (0.031 - 0.38in)0.48 - 0.67mm (0.019 - 0.026in) (Modified)
    Carrier Substrate99.9% silver99.9% silver
    Carrier Length2.74 - 2.85mm (0.108 - 0.112in)2.74 - 2.85mm (0.108 - 0.112in)
    Carrier Diameter0.48 - 0.53mm (0.019 - 0.021in)0.27 - 0.33mm (0.011 - 0.013in) (Modified)
    IsotopeIodine I-125Iodine I-125
    SterilizationNot sterile (User sterilized)Not sterile (User Sterilized)
    Other Performance
    Sealed Source IntegrityMet ISO 2919 requirementsTested according to ISO 2919 for sealed sources
    Activity Measurement-Obtained from NIST Report (Air-Kerma rate measurements)
    Design Validation-Prototype sources manufactured and assessed against predetermined criteria for Design Verification and Design Validation

    Note on Acceptance Criteria: For a 510(k) submission, "acceptance criteria" are largely based on demonstrating substantial equivalence to a predicate device. This means the new device should be as safe and effective as the predicate, often by meeting the same or equivalent engineering specifications and performance standards. In this case, the predicate's characteristics serve as the de facto acceptance criteria that the new device aims to match or justify deviations from. The substantial equivalence is based on the argument that the modified characteristics (smaller diameter) do not raise new questions of safety or effectiveness, especially since other critical parameters (like capsule material, isotope, length ranges) remained the same.

    2. Sample Size for Test Set and Data Provenance

    The document does not specify a "test set" in the context of an AI/ML algorithm or a study involving patient data. This is a physical medical device. The "testing" involved:

    • Physical Prototypes: "Prototype sources have been manufactured and assessed against predetermined criteria for Design Verification and Design Validation." The exact number of prototypes is not specified.
    • Sealed Source Testing: The device was tested according to ISO 2919, which is a standard for sealed radioactive sources. This likely involves a series of physical tests (e.g., temperature cycling, external pressure, impact, vibration, puncture) on a sample of devices to ensure their integrity. The sample size for these specific tests is not explicitly stated in the 510(k) summary, but ISO standards typically define sample requirements.
    • Activity Measurements: "Activity measurements have been obtained from NIST Report (Report of Air-Kerma rate measurements)." This refers to calibration and measurement standards from the U.S. National Institute of Standards and Technology.

    Data Provenance: Not applicable in the context of patient data as this is a physical device safety and performance evaluation. The provenance of the testing (e.g., "NIST Report") is mentioned, indicating U.S. national standards.

    3. Number of Experts Used to Establish Ground Truth and Qualifications

    Not applicable. This is a physical device, not a diagnostic imaging or AI algorithm that relies on expert interpretation of data to establish ground truth.

    4. Adjudication Method for the Test Set

    Not applicable. There is no "test set" of patient cases requiring expert adjudication.

    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

    No. This type of study is relevant to diagnostic imaging devices or AI algorithms where human readers interpret medical images. It is not applicable to a radioactive implantable seed.

    6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

    Not applicable. This device is a physical brachytherapy source, not an algorithm.

    7. The Type of Ground Truth Used

    The "ground truth" for this device is based on engineering specifications, international standards (ISO 2919), and national metrology standards (NIST).

    • Device Specifications: The stated dimensions, materials, and isotope are the design "ground truth."
    • Performance Standards: Compliance with ISO 2919 for sealed source integrity ensures the physical safety and containment of the radioactive material.
    • Radioactivity Calibration: NIST reports provide the "ground truth" for the accurate measurement of the device's radioactive output (Air-Kerma rate), which is critical for safe and effective dosimetry in patient treatment.

    8. The Sample Size for the Training Set

    Not applicable. There is no "training set" for this physical medical device.

    9. How the Ground Truth for the Training Set Was Established

    Not applicable. There is no "training set" for this physical medical device.


    Summary of the Study Proving Acceptance Criteria:

    The "study" proving the device meets acceptance criteria consists of non-clinical testing focused on the physical and radiological properties of the brachytherapy source.

    1. ISO 2919 Testing: The device underwent testing "according to ISO 2919 for sealed sources." This standard specifies the classification of sealed radioactive sources based on their safety requirements and defines a series of environmental and mechanical tests (e.g., temperature, external pressure, impact, vibration, puncture) designed to demonstrate that the source will maintain its integrity and containment of radioactive material under normal and accident conditions. Meeting this standard indicates the physical robustness and safety of the sealed source.
    2. NIST Report for Activity Measurements: "Activity measurements have been obtained from NIST Report (Report of Air-Kerma rate measurements)." This confirms that the radioactive output of the device (Iodine-125) has been accurately measured and calibrated to national standards as verified by the National Institute of Standards and Technology. Accurate activity measurement is fundamental for physicians to calculate appropriate treatment dosages for patients.
    3. Design Verification and Design Validation: "Prototype sources have been manufactured and assessed against predetermined criteria for Design Verification and Design Validation." This process ensures that the manufactured device meets its design specifications (verification) and fulfills its intended use requirements (validation). This typically involves comparing actual prototype performance against the established design requirements and user needs.

    These non-clinical tests demonstrate that the Brachytherapy Source Device, Model 9011, is physically safe, robust, and accurately characterized in terms of its radioactive output, thereby establishing its substantial equivalence to the predicate device despite minor dimensional changes.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1